UPCC 15217: A Pivotal Trial of ARQ 087 | Clinical Research Studies Listing

UPCC 15217: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Recruiting

18 years - 99 years

All

Phase 3

5 participants needed

1 Location

Brief description of study

The main purpose of this study is to find out if the study drug ARQ 087 is safe and effective to use in patients with intrahepatic cholangiocarcinoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Cholangiocarcinoma
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 827501

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 15217: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Brief description of study

Eligibility of study

Find a site

Interested in the study